Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504229 | 0.82 | NAMPT (0.50) | ROCK2ROCK1SMN1; SMN2KDM4EHTT | |
| SCHEMBL3503297 | 0.80 | NAMPT (0.58) | ROCK2ROCK1KDM4ENAMPTMAPT | |
| SCHEMBL3504648 | 0.79 | ROCK2 (0.60) | ROCK2ROCK1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3502434 | 0.79 | ROCK2 (0.65) | ROCK2ROCK1SMN1; SMN2KDM4EHTT | |
| SCHEMBL3504202 | 0.78 | ROCK2 (0.58) | ROCK2ROCK1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL3502405 | 0.78 | ROCK2 (0.60) | ROCK2ROCK1KDM4EL3MBTL1NAMPT | |
| SCHEMBL3502633 | 0.78 | RAB9A (0.56) | ROCK2ROCK1SMN1; SMN2KDM4EHTT | |
| SCHEMBL3504672 | 0.77 | ROCK2 (0.56) | ROCK2ROCK1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3502656 | 0.76 | NAMPT (0.57) | ROCK2ROCK1SMN1; SMN2NPC1KDM4E | |
| SCHEMBL3500616 | 0.75 | ROCK2 (0.51) | ROCK2ROCK1SMN1; SMN2NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190788-A1 | Amide derivatives as kinase inhitors | DEVGEN N.V. (BE) | 2010-07-29 | — | — | US | claimed |
| EP-1907362-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | Devgen NV (BE) | 2008-04-09 | — | — | EP | claimed |
| WO-2007006547-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | claimed |
| US-20100190788-A1 | Amide derivatives as kinase inhitors | DEVGEN N.V. (BE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190788-A1 | Amide derivatives as kinase inhitors | MAP3K1, MAPK1, MAP3K21 | ROCK2 24/4885ROCK1 10/4885SMN1; SMN2 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.